Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

BRAF G469V

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

BRAF L485-P490 deletion (6)

BRAF amplification (1)

BRAF L485-P490 deletion (6)

BRAF amplification (1)

›

BRAF G469V	Solid Tumor	BRAF G469V	Solid Tumor	BVD-523 Sensitive: B - Late Trials BVD-523 Sensitive : B	BVD-523 Sensitive: B - Late Trials BVD-523 Sensitive : B
BRAF G469V	Non Small Cell Lung Cancer	BRAF G469V	Non Small Cell Lung Cancer	trametinib + dabrafenib Resistant: C3 – Early Trials trametinib + dabrafenib Resistant : C3	trametinib + dabrafenib Resistant: C3 – Early Trials trametinib + dabrafenib Resistant : C3
BRAF G469V	Non Small Cell Lung Cancer	BRAF G469V	Non Small Cell Lung Cancer	trametinib Resistant: C3 – Early Trials trametinib Resistant : C3	trametinib Resistant: C3 – Early Trials trametinib Resistant : C3
BRAF G469V	Non Small Cell Lung Cancer	BRAF G469V	Non Small Cell Lung Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
BRAF G469V	Non Small Cell Lung Cancer	BRAF G469V	Non Small Cell Lung Cancer	sorafenib Sensitive: C4 – Case Studies sorafenib Sensitive : C4	sorafenib Sensitive: C4 – Case Studies sorafenib Sensitive : C4
BRAF G469V	Lung Adenocarcinoma	BRAF G469V	Lung Adenocarcinoma	gefitinib Sensitive: D – Preclinical gefitinib Sensitive : D	gefitinib Sensitive: D – Preclinical gefitinib Sensitive : D
BRAF G469V	Lung Adenocarcinoma	BRAF G469V	Lung Adenocarcinoma	osimertinib Sensitive: D – Preclinical osimertinib Sensitive : D	osimertinib Sensitive: D – Preclinical osimertinib Sensitive : D